ation and attenuates the malignant phenotype (5, 7, 8, 11 NFκB also attenuate AP-1 activity (15,16). These data suggest There is evidence that reactive oxygen species (ROS) are that common upstream signaling cascades may be involved important mediators of tumor promotion and progression.
NFκB also attenuate AP-1 activity (15, 16) . These data suggest There is evidence that reactive oxygen species (ROS) are that common upstream signaling cascades may be involved important mediators of tumor promotion and progression.
that mediate elevated AP-1 as well as NFκB transactivation The molecular mechanisms involved in ROS-mediated during tumor progression. While some common effectors of signaling, however, are unclear at present. Using ioniz-NFκB and AP-1 activity are known, their role during malignant ing radiation and N-methyl-NЈ-nitro-N-nitrosoguanidine progression of skin tumors and the molecular mechanisms (MNNG) as model physical and chemical carcinogens, involved therein remain poorly understood. we have malignantly progressed 308 cells, a papillomaReactive oxygen species (ROS) are an important class of producing mouse keratinocyte cell line, and investigated these effector molecules. ROS such as superoxide (O 2 -·), the molecular alterations in the progressed phenotypes. In hydrogen peroxide (H 2 O 2 ) and hydroxyl radical (OH·) are this study, we demonstrate that both MNNG and radiationnormal biproducts of intracellular metabolic processes. These progressed malignant variants showed elevated ROS levels and other oxidant species are highly reactive and can produce that contributed to their proliferative capacity in vitro as macromolecular damage (17) . There is evidence that ROS can well as in vivo. We found increased Erk-1/2 and p38 MAP act as activators of transcription factors and modulate their kinase activities to be important components of ROSactivity either directly or indirectly by activating other signaling mediated signaling. The pro-oxidant state also contributed cascades. NFκB transactivation has been shown to be redoxto constitutive elevation of AP-1, NFκB and cAMP response sensitive at two levels: (i) phosphorylation of the inhibitor element transactivation in the malignant phenotype. Our I-κB is mediated by oxidation; and (ii) a Ref/thioredoxindata provide evidence for a functional role of elevated ROS dependent binding of the p50 subunit to the DNA is governed levels in tumor progression and implicate Erk-1/2 and p38 by the reduction of an essential cysteine group. NFκB activation MAP kinase activation in the malignant progression of can be triggered by oxidants in the absence of any physiological mouse keratinocytes. stimulus and is inhibited by a broad range of chemically unrelated antioxidants (18) . AP-1 DNA binding activity has also been shown to be modulated by Ref/thioredoxin-dependent Introduction reduction of cysteines in c-Jun and c-Fos (19) . In addition, An accepted paradigm for neoplastic transformation is the active oxygen has been shown to induce c-fos expression (20) . multistep model of carcinogenesis in mouse skin, which Mitogen-activated protein kinases (MAPKs), a group of involves initiation, promotion and progression (1,2). Initiation serine/threonine-specific, proline-directed protein kinases (21), involves mutational activation of a cellular proto-oncogene.
are also known to modulate transcription factor activities. They Tumor promotion involves the selective clonal expansion of are a part of kinase cascades that serve as information relays, the initiated cell population (3), whereas the final stage connecting extracellular stimuli to specific transcription factors (progression) involves irreversible malignant transformation thereby allowing these signals to regulate specific gene expresfrom pre-neoplastic lesions (4).
sion. There are three subtypes of MAPKs: the extracellular Investigations into the molecular mechanisms of tumor signal regulated kinases (Erks), the c-Jun N-terminal kinases progression have revealed that this operational step involves (JNKs) and the p38 MAPKs. Current evidence indicates that modulation of transcription factors. A causal relationship while Erks are predominantly stimulated by mitogens, JNKs has been established between neoplastic transformation and and p38 MAPK are a part of the stress response pathways transcription factor AP-1 transactivation (5) (6) (7) (8) . Over-expresactivated by cellular stress induced by agents like heat, UV sion of this heterodimeric complex (9) leads to increased and ionizing radiation and inflammatory cytokines mediating neoplastic transformation (10) . Constitutive elevation of AP-1 inhibition of cell proliferation or cell death (22, 23) . AP-1 activity has been correlated with malignant conversion of activity has been shown to be modulated by MAPKs in papillomas to carcinomas (11) . Tumor promoters like TPA and response to various stimuli (24). NFκB activation has been okadaic acid efficiently induce AP-1 activity (12, 13 levels may play a functional role in the pathogenesis of cancer prepared and analyzed by a luciferase assay as described previously (44 luminescence recorded immediately for 1 min with a Monolight 2010 The cells were maintained in minimal essential medium (MEM) supplemented luminometer (38). The luminol assay was done by incubating cells in 1 mg/ml with 7.5% fetal calf serum (FCS), 2.5% calf serum (CS) and 100 U/ml luminol in HPBS and measuring luminescence using a Beckman Liquid penicillin/streptomycin (Gibco BRL, Grand Island, NY) at 37°C in a humidified Scintillation Counter set in a single photon emission mode (48). Background atmosphere containing 7.5% CO 2 . For in vitro malignant transformation, Ͼ10 7 luminescence from inserts alone was subtracted in both assays. For the NAC 308 cells in late log-phase culture were treated with LD 90 doses of either attenuation studies, the cultures were treated with indicated concentrations of MNNG (2.5 µM; Sigma, St Louis, MO) or γ rays (750 cGy) from a 60 Co the agent for 16 h prior to the assay. Results from a representative of three source. The cultures were trypsinized immediately following treatment and experiments are shown. plated at clonal density. The survivors were pooled, grown to Ͼ10 7 as before and re-treated. A total of six such generations were created. Parallel flasks of Growth curves and clonogenic survival assays 308 cells were mock treated and passaged under similar conditions as the Cells (5ϫ10 5 ) were plated in 100 mm dishes and grown for 3 days as treated cells.
described. These dishes were trypsinized every 12 h in triplicate and the cells The sixth generation radiation-or MNNG-progressed as well as mockcounted on a Coulter Counter. Mean cell numbers were plotted against time treated 308 cells were injected s.c. into athymic nude mice (Charles River on a log-linear scale to generate growth curves for all three cell lines. Data Labs, Wilmington, MA) at 10 6 cells per site and followed for tumor growth.
from a representative of three experiments are shown. For clonogenic survival One randomly selected tumor from each of the MNNG and radiation groups assays, 500 cells were plated in 60 mm dishes and treated in triplicate under was put into culture to establish cell lines according to previously established identical conditions as DNA synthesis assays. The cultures were then grown protocols (42). These MNNG (6M90)-and radiation (6R90)-progressed tumor for another 7-10 days, stained with Coomassie and the number of colonies cell lines were maintained in culture under identical conditions as mockcounted (data not shown). passaged sixth generation 308 cells. All experiments were done using cultures with passage numbers between passage five and 15. The 308 cells described Isolation of nuclear protein and western analysis in the experiments are the mock-treated sixth generation 308 cells.
Nuclear protein was isolated from subconfluent cultures using published Transactivation analysis protocols (49). Briefly, the cells were rinsed with PBS and buffer A, pelleted and then lysed with 0.1% NP-40 in buffer A. Nuclei were pelleted by A total of 1.5ϫ10 5 308 cells as well as 6M90 and 6R90 variants were plated centrifugation and the proteins extracted in buffer C. The extracts were stored in 6-well dishes and transiently transfected in triplicate using DOTAP liposomal at -80°C diluted 1:6 with buffer D until used. The protein concentrations of transfection reagent (Boehringer Mannheim, Indianapolis, IN). Luciferase the extracts were determined with Bio-Rad reagent (Bio-Rad, Hercules, CA). reporter construct, driven by either a human collagenase TPA response element Nuclear extract (20 µg) was resolved on a 10% SDS-polyacrylamide gel and (TRE), NFκB sites from the HIV genome (NFκB) or cAMP response element analyzed by western blot using antibodies against p65 NFκB (1:250 dilution; (CRE) from the Intracisternal A-type Particle gene, was used at 5 µg/well. Santa Cruz Biotechnology, La Jolla, CA) and Threonine-71 phosphorylated These constructs were a kind gift from Dr Zigang Dong and have been ATF-2 (1:100 dilution; New England Biolabs). Individual band intensities described previously (8, 43) . Parallel plates were transfected with the empty were quantified by digitizing the radiographs on EagleEye (Stratagene, Santa luciferase vector as controls. The cells were recovered after 24 h posttransfection with or without serum as described in Results. Cell lysates were Cruz, CA) and then analyzing the image using ONEDSCAN software.
In vitro protein kinase assays
Cells from subconfluent cultures were lysed in 20 mM Tris pH 7.5, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium vanadate, 1 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride. Protein (100 µg) was incubated with phospho-specific ERK-1/2 antibody, phospho-specific JNK antibody or phospho-specific p38 MAPK antibody (New England Biolabs) with gentle rocking overnight at 4°C. Protein A sepharose beads were added and the mixture rotated for another 3 h, washed twice in lysis buffer and twice in kinase buffer (25 mM Tris pH 7.5, 5 mM β-glycerophosphate, 2 mM DTT, 0.1 mM sodium vanadate and 10 mM MgCl 2 ). Beads were suspended in 50 µl kinase buffer with 100 µM ATP and 0.5 µg substrate (Erk-1/2, Elk-1; JNK, c-Jun; p38 MAPK, ATF-2; Santa Cruz Biotechnology) and incubated for 30 min at 30°C. Samples were then boiled in SDS sample buffer and resolved on 12.5% SDS-polyacrylamide gels. Phosphorylated substrates were visualized by western blot using phospho-specific antibodies for the different substrates (New England Biolabs). Individual band intensities were quantified by densitometric analysis of the radiographs as before.
Results

In vitro tumor progression model
The benign papilloma-producing mouse keratinocyte cell line 308 has been shown to acquire a transformed phenotype following treatment with tumor promoters (8) and physical carcinogens (6) . We used subconfluent cultures of 308 cells to establish an in vitro model of malignant progression using ionizing radiation and MNNG as model physical and chemical carcinogens, respectively. After six consecutive LD 90 treatments, the survivors as well as mock-treated 308 cells were injected s.c. into athymic nude mice and followed for tumor development. The first tumors were seen 8 weeks post-injection in the MNNG group and at 10 weeks in the radiation group. By 12 weeks post-injection, more than two-thirds of the sites injected with either MNNG-or radiation-progressed survivors showed progressively growing tumors. In contrast, mocktreated 308 cells remained non-tumorigenic up to 20 weeks tumor cell lines produced aggressively growing tumors 2-3 weeks post-injection. Figure 1 shows the growth characteristics of these cell lines 308 cells (P Ͻ 0.05). These data suggest that the 308 malignant in culture. After an initial lag phase, the 6M90 and 6R90
variants have an increase in growth fraction, which accounts cultures had higher growth rates as compared with 308 cells for their higher growth rate in culture. and by the end of 5 days had 35-50% more cells in growth Both 6M90 and 6R90 cells have elevated NFκB and CRE assays (P Ͻ 0.05; Figure 1A ). To determine if these differences transactivation as well as increased Erk-1/2 and p38 MAPK in growth characteristics were statistically significant, the cell activity numbers were converted into their log values and plotted against time on a linear scale. The slopes of the curves were
To determine the transactivation potential via different ciselements, cell lines were transiently transfected with luciferase calculated by a linear regression analysis (data not shown). A Student's t-test was performed to determine the level of constructs driven by AP-1, NFκB or CRE dependent promoters.
To determine if the transactivation potential through these cissignificance for the differences observed in the slopes. Based on these analyses the slopes of the curves for the malignant elements was dependent on growth factors, luciferase activities were measured in cultures recovered either in the absence or 6M90 and 6R90 cell lines were found to be significantly higher as compared with the benign 308 cells (P Ͻ 0.05). The plating presence of serum. Figure 2 shows the results from the luciferase assays. In the absence of serum ( Figure 2A ) the efficiencies were estimated to be between 75 and 80% for all the cell lines. The cloning efficiencies for 308 cells as well as 6M90 showed elevated AP-1 (3.3-9.4-fold), NFκB (5.0-10.5-fold) and CRE (2.3-3.7-fold) transactivation as compared with their malignant variants were also found to be very similar and did not account for the increased proliferation seen in 308 cells. The radiation-progressed 6R90 did not show any increase in AP-1 activity over 308 cells. However, statistically 6M90 and 6R90 cultures (data not shown). DNA synthesis assays ( Figure 1B) showed that the malignant cell lines had significant elevations in NFκB (1.7-2.8-fold) and CRE (1.8-2.9-fold) transactivation were seen (P Ͻ 0.05) in these cells. 30-70% elevation in [ 3 H]thymidine uptake as compared with In the presence of serum (Figure 2B ), the progressed cell lines in parallel experiments. Rates of overall protein synthesis, as measured by [ 35 S]methionine uptake were also found to be maintained significantly elevated transcription factor activities compared with 308 cells, suggesting that elevated transactivsimilar amongst the 308 and the malignant variants (data not shown). ation potential from NFκB and CRE cis-elements was constitutive in 6M90 and 6R90 malignant cells. In addition, the 6M90
To determine the potential mechanisms for constitutively elevated transactivation via NFκB and CRE cis-elements, cell line also had a constitutive elevation of AP-1 activity. In order to determine the specificity of this elevation in nuclear extracts from all cell lines were analyzed for NFκB p65 and phosphorylated ATF-2 levels ( Figure 2C ). Significant transactivation potential, transfections with parent luciferase vector lacking these cis-elements were done. No significant elevations in nuclear levels of p65 NFκB were seen in both 6M90 as well as 6R90 cells (2.5-3.8-fold over 308 levels). differences in luciferase activities were found amongst the cell lines (data not shown). The transcription factor specificity of ATF-2 phosphorylation at Thr-69 and Thr-71 within its N-terminal activation domain has been shown to stimulate its the luciferase constructs is also indicated by the fact that whereas significant elevation in AP-1 transactivation was transcriptional activity (50) . The 308 nuclear extracts showed barely detectable levels of transcriptionally activated ATF-2, detected in 6M90 cells, AP-1 activity in 6R90 variants was unaltered as compared with 308 cells. Transfection efficiencies while substantially increased levels of Thr-71 phosphorylated ATF-2 were detectable in 6M90 as well as 6R90 cells. While in the three cell lines were determined to be very similar (between 7-9%) by transfecting a CMV-driven β-gal reporter these findings suggested a potential mechanism of elevated Exponentially growing cultures were serum starved for 24 h. The cells were lysed and 100 µg total cell extract were immunoprecipitated with phosphospecific antibodies for Erk-1/2, JNK or p38 MAPK. In vitro kinase assays were performed and phosphorylated substrates were detected by western blot analysis using phospho-specific antibodies. Representative blots from three experiments are shown. cell extracts from subconfluent cultures grown without serum were analyzed for individual MAPK activities by an in vitro analyzed the ROS status of 308 cells and the malignant kinase assay (Figure 3 ). In these assays, the 308 cells showed variants. Levels of intracellular ROS were measured using low levels of Erk-1/2 activity. In contrast, Erk-1/2 activity was lucigenin and luminol enhanced chemiluminescence assays found to be significantly elevated in 6M90 cells (2.5-4.0-fold).
( Figure 4A and B respectively). Lucigenin enhanced chemip38 MAPK activity was barely detectable in 308 cells under luminescence has specificity for O 2 -·, whereas luminol detects these conditions whereas both 6M90 as well as 6R90 lysates hydrogen peroxide and singlet oxygen generation (38,48). showed elevated p38 activity. JNK activity did not appear to With both assays, the 6M90-as well as 6R90-progressed cells be significantly different amongst the three cell lines. Taken showed a near 2-fold elevation in steady state ROS levels together, these data show that, in this model, increased (range 1.6-2.4-fold between experiments; P ϭ 0.05). In transcription factor and MAPK activities correlate with the general, there was a trend towards a higher chemiluminescence malignantly progressed phenotype.
with lucigenin in 6R90 cells ( Figure 4A ), whereas the 6M90
Malignant variants have increased intracellular ROS levels
cells showed elevated signals with luminol ( Figure 4B) , that contribute to their proliferative capacity suggesting that there might be differences in ROS species between these cell lines. 308 cells have an activated ras gene (41). Recently, ROS have been shown to be involved in ras signaling (38). We therefore
Since acute exposure to active oxygen has been shown to 20-30% attenuation in DNA synthesis was seen in the malignant 6M90 and 6R90 cells, whereas a Ͼ50% attenuation was seen in 308 cells. Treatment with 30 mM NAC appeared to be necessary to attenuate DNA synthesis in malignant cell lines. Trolox, an analog of Vitamin E and a chemically unrelated antioxidant, was much less effective in attenuating cell proliferation as compared with NAC ( Figure 5B ). 308 cells were more sensitive to inhibition with 2 mM Trolox as compared with 6R90 cells. Furthermore, an ineffective (1 mM) dose of Trolox potentiated the inhibitory effects of 10 mM NAC, suggesting that these agents predominantly exerted an antioxidant effect in our assays. All the treatment doses were evaluated for toxicity by clonogenic survival assays. No significant differences in cloning efficiencies were observed between treated cells versus control cells (data not shown).
We further confirmed the specificity of NAC effects by measuring ROS levels in the presence of 5 and 20 mM NAC. A dose-dependent attenuation in lucigenin enhanced chemiluminescence was seen ( Figure 5C ). More significantly, higher residual luminescence was observed in both 6M90 and 6R90 cell lines compared with 308 cells at both the doses tested. These data demonstrate that the malignant variants have a higher ROS level as compared with the benign 308 cells. Treatment with equimolar doses of antioxidant NAC attenuates DNA synthesis more effectively in 308 cells. At doses of up to 20 mM NAC, significantly higher residual levels of ROS persist in both 6M90 as well as 6R90 variants that maintain elevated DNA synthesis in these cells. A higher (30 mM) dose of NAC is necessary to attenuate DNA synthesis in these malignant variants to a level similar to low-dose treatment of 308 cells. Taken together, these data functionally implicate elevated ROS levels in the malignant progression of 308 cells.
To test if the tumorigenic phenotype of the malignant variants was dependent on their pro-oxidant state, we studied the effects of another antioxidant, PDTC, in vivo by treating athymic nude mice bearing 6M90 or 6R90 tumor xenografts. The choice of this antioxidant was based on the fact that in vitro treatment with 100 µM PDTC resulted in Ͼ50% attenuation of DNA synthesis in these cell lines as was seen Gross analysis of the cut sections of the tumors at the end of the experiment showed evidence of residual solid, potentially viable, tumor mass in PDTC-treated animals. While these be mitogenic (51), we hypothesized that elevated steady state results demonstrate that elevated ROS levels in these malignant ROS levels could mediate the observed increases in cell variants are important for tumor growth in vivo as well as proliferation in the malignant variants. To test this hypothesis, in vitro, a lack of complete abrogation of the tumorigenic we analyzed the effects of antioxidant treatments on DNA phenotype points towards additional, ROS-independent synthesis in the 308 cells as well as the malignant variants. mechanisms being involved in the maintenance of the NAC treatment attenuated DNA synthesis in all cell lines in phenotype. a dose-dependent manner ( Figure 5A ). 308 cells were found Pro-oxidant state of 6M90 and 6R90 cell lines mediates to be significantly more sensitive to inhibition at equimolar elevated Erk-1/2 and p38 MAPK activities and, in part, doses of NAC than the progressed cell lines. Treatment with elevated transcription factor activities as low as 5 mM NAC resulted in a 38% (range 25-45%) inhibition in DNA synthesis in 308 cells whereas the progressed Having shown that the elevated ROS levels functionally contribute to the proliferative capacity of the progressed cell lines remained largely unaffected. With 20 mM NAC a Fig. 6 . Antioxidant PDTC attenuates in vivo tumor growth from 6M90 and 6R90 cell lines. Cells (5ϫ10 6 ) from late log-phase cultures were injected s.c. into athymic nude mice. When the tumors from 6M90 (A) and 6R90 (B) cells reached a mean size of 50-100 mm 2 , the mice were given thrice weekly injections of either PDTC (100 mg/kg) or saline and followed for tumor growth. Error bars represent standard deviation of the means. The data represent means from eight mice in each treatment group.
variants, we proceeded to investigate the potential signaling cascades involved in this process. It has been shown previously that ROS can act as signaling molecules and can modulate transcription factor and MAPK activities (17) (18) (19) (20) 27, 28) . In order to determine whether elevated ROS levels signaled via these effector targets in our model, we performed attenuation studies with NAC. Figure 7 shows the effects of NAC treatment on AP-1 (graph A), NFκB (graph B) and CRE (graph C) luciferase reporter activities. NAC treatments (20 mM) resulted in a 50% inhibition of NFκB and AP-1 transactivation in 308 cells ( Figure 7A and B), which correlates with the extent of inhibition of DNA synthesis with NAC in these cells. However, a majority (nearly 75%) of the AP-1 as well as NFκB are, in part, independent of the pro-oxidant state of these cells, and their constitutive elevation involves other mechanisms. The modulation of CRE-dependent transactivation with NAC studies show that elevation of Erk-1/2 and p38 MAPK correlate was interesting in that the transactivation in 6R90 cells appeared with the malignant progression of 308 cells. Studies with the to be attenuated to a greater extent than the 308 cells (Figure antioxidant NAC suggest that elevation of steady state ROS 7C), suggesting that ROS levels may significantly modulate levels in these cells may be responsible for the constitutive CRE-dependent transactivation in 6R90 cells. These studies activation of these MAPK in the 6M90 and 6R90 malignant suggested that both ROS-dependent as well as ROS-independvariants. ent mechanisms influenced signaling via these transcription Both Erk-1/2 as well as p38 MAPK signaling pathways are factors. This prompted us to study the effects of NAC treatment important in maintaining cell proliferation on MAPK activities Figure 8 shows the effects of increasing doses of NAC on To investigate the role for ROS-mediated elevated Erk-1/2 and p38 MAPK in proliferative capacity of the malignant Erk-1/2 and p38 MAPK activities. As was seen in serumstarved cells (Figure 3 ), Erk-1/2 activity in 6M90 cells was phenotype, we used pharmacological inhibitors to attenuate signaling via these kinases. We inhibited Erk-1/2 activity with found to be elevated (1.8-2.5-fold) in cycling cells, indicating a constitutively elevated Erk-1/2 signaling cascade in these PD 98059, which is a specific inhibitor of Erk-1/2 activating kinases MEK-1/2 (52). We have shown previously that 50 µM cells ( Figure 8A ). Furthermore, a dose-dependent attenuation of Erk-1/2 activity was seen with NAC in this MNNG-PD 98059 completely abrogates Erk-1/2 activity in 308 cells (44) . We also found this to be true for both 6M90 as well as progressed malignant variant. Treatment with a 5 mM dose appeared to bring the activity level down to that seen in 6R90 cells (data not shown). Inhibition of Erk-1/2 activity in all cell lines resulted in a significant (35-45%) attenuation of untreated 308 cells. p38 MAPK activity showed a dosedependent attenuation in all three cell lines ( Figure 8B ). 6R90 DNA synthesis ( Figure 9 ) suggesting that in this model system, the Erk-1/2 cascade transduces a mitogenic signal. SB 203580, cells showed a significant elevation of p38 activity (2.3-3.5-fold) as compared with 308 cells. Taken together, the MAPK a pyridinyl-imidazole compound that inhibits p38 MAPK (53) which resulted in a Ͼ50% attenuation of DNA synthesis in these cells. The MNNG-progressed 6M90 cells as well as 308 cells were also inhibited but to a lesser extent.
Discussion
Deregulated gene expression due to perturbations in signal transduction pathways can lead to abnormal cellular responses including malignant conversion. Our finding that AP-1 activity is constitutively elevated in 6M90 cells agrees with the evidence for a causal relationship between elevated AP-1 transactivation and malignant progression of murine skin tumors and human keratinocytes (6, 11, 16) . We did not see a similar increase in 6R90 cells, suggesting the involvement of AP-1 independent mechanisms in the progression of this variant. Recently, elevated NFκB activity has also been implicated in this process (8, 16) . Our analysis of the 6M90 and 6R90 malignant variants extends these observations to include elevated nuclear levels of p65 subunit as a potential mediator of increased NFκB transactivation. This subunit has been shown to be necessary for optimal transactivation and induction of NFκB-dependent genes (54) (55) (56) . In addition, 'cross-talk' between AP-1 and NFκB transcription factors can also occur via p65 NFκB subunit interaction with AP-1 proteins (57). NFκB activity and provide support for its elevated nuclear increasing doses of NAC. After 16 h of treatment, cells were lysed and levels as a potential mechanism for increased NFκB transactiv-100 µg of total protein were immunoprecipitated with phospho-specific antibodies for Erk-1/2 (A) or p38 MAPK (B). In vitro kinase assays were ation observed in the 6M90 and 6R90 malignant variants. This performed and phosphorylated substrates were detected by western blot increased nuclear localization could be a result of either a analysis using phospho-specific antibodies. Representative blots are shown.
transcriptional induction of p65 or decreased levels of its
The experiment was repeated three times.
cytoplasmic inhibitor IKBα (58) . Additional post-translational modifications of p65, such as phosphorylation, have been shown to increase its DNA binding (59) and transactivation was used to study the effects of p38 MAPK inhibition on cell proliferation. SB 203580 (20 µM) inhibited 85-90% MAPK-2 (60) potential. The contributions of these mechanisms to elevated NFκB transactivation in this model system is an area phosphorylation and did not decrease Erk-1/2 or JNK phosphorylation (data not shown) in these cells substantiating its of further study.
We have made a novel observation of elevated CRE transspecificity as a p38 MAPK inhibitor. The 6R90 cells were found to be extremely sensitive to p83 MAPK inhibition, activation in the malignant phenotype. CRE is found in the promoters of genes such as those responsive to protein kinase mediated responses may be quite different. The p38 MAPK inhibitor SB 23580, which we used in our studies, inhibits A activation (61) . This octameric site preferentially binds c-Jun/ATF-2 heterodimers (62) and appears to be constitutively only the α and β isoforms of p38 MAPK (53, 71) . It is possible that both 6M90 as well as 6R90 cells have elevated p38β occupied in non-stimulated cells (63) . Phosphorylation of threonine residues in the transactivation domain of ATF-2 by activity as a dominant component of p38 MAPK activity that mediates a cell survival response. Further studies are needed to stress-activated protein kinases, such as p38 MAPKs, are required for transcriptional activation of this prebound complex characterize the p38 subtypes in modulating cellular responses. In this study we show that both MNNG-progressed 6M90 (50) . The CRE cis-element has been shown to play an important role in the transcriptional activation of c-Jun (63) and proteases as well as ionizing radiation-progressed 6R90 cells show elevated ROS levels that contribute to their increased prolifersuch as uPA (64) , genes that may play a functional role during tumor progression. We hypothesize that alterations in CRE ative capacity. Attenuation studies with the antioxidant NAC have identified Erk-1/2 and p38 MAPK as well as potential activity plays a functional role in malignant progression by effecting expression of such genes.
targets mediating the mitogenic response of elevated ROS levels. These results are consistent with the observations that In our transient transfection studies, we used a CMVdriven β-gal expression vector to normalize for transfection acute exposure to X-rays or MNNG can induce MAPKs in a redox-sensitive manner (74,75). We speculate that elevated efficiencies. Initially, we cotransfected this expression plasmid with the luciferase reporter constructs and attempted to normal-ROS levels can increase MAPK signaling during malignant progression that provides the necessary growth advantage for ize the data based on the β-gal activity measured in each transfection. However, we found that the β-gal activity, as the emergence of the transformed phenotype. Our results suggest that elevation of transcription factor activities via measured by an enzymatic assay, was always 2-4-fold higher in the malignant variants as compared with 308 cells (data not MAPK activation and/or redox modulation is also a part of ROS-mediated mitogenic signaling. The mechanism by which shown). We suspected that this could be due to differences in CMV promoter activity in the cell lines, rather than a difference ROS modulate the activity of MAPK is unknown at present. Recently, Irani et al. (38) have shown that oncogenic ras in transfection efficiencies. Therefore, we employed an alternative approach and stained the cells under identical transfection increases the production of superoxide anion that contributes to increased cell proliferation. However, our data are significantly conditions for β-gal expression. In these experiments between 7-9% cells stained positive for β-gal. These results suggest different from the results of their study. ROS-induced mitogenic signaling was found to be independent of MAPKs in the NIH that the transfection efficiencies between the cell lines were indeed similar and that the difference in β-gal activity was 3T3 fibroblast clone A6 analyzed by Irani et al. (38), whereas our results show that elevated Erk-1/2 and p38 MAPK activities perhaps due to CMV promoter related differences. Our contention is supported by a recent observation that activation of are important components of ROS-mediated mitogenic signaling in the malignantly progressed variants. Whereas the ras MAPK up-regulates expression of CMV driven transgene expression in cells (65) . mutation in 308 keratinocytes involves codon 61, the A6 clone caries a valine-12 mutant (38,41). We speculate that different MAPKs are important upstream regulators of transcription factor activities. In this study we demonstrate that the malignant ras mutants may activate different signaling cascades. Our contention is supported by studies with another ras-transformed variants have elevated Erk-1/2 and p38 MAPK activities that are important in maintaining optimal cell proliferation.
3T3 clone that carries a V12-S35 mutant and has a constitutively activated MAPK pathway (76). Our preliminary analysis Increased AP-1 and/or NFκB transactivation, as seen in the 6M90 cells, could be among some of the downstream effects of ras involvement in our model suggests that cell proliferation in the malignant variants is ras dependent (data not shown). of elevated Erk-1/2 activity. Erk-1/2 signaling has been shown to play an functional role in malignant transformation in other In summary, our results provide evidence that emergence of a pro-oxidant state plays a functional role in the malignant cell types (66, 67) . De-regulation of this signaling cascade may, therefore, be a critical determinant of malignant progression.
progression of mouse keratinocytes. We have made a novel observation of increased CRE transactivation in the tumori-AP-1 and/or NFκB transcription factors are potential downstream mediators of Erk-1/2 activation. genic phenotype. Our data suggest that transcription factors and MAPKs are potential targets involved in ROS-mediated In our model system, we demonstrate that the 6R90 cells have a constitutively elevated p38 MAP kinase activity that is mitogenic signaling and, for the first time, implicate elevated Erk-1/2 and p38 MAPK signaling in tumor progression. critical for its proliferative capacity. The role of p38 signaling in cellular responses to various stimuli remains poorly understood and is controversial at present. Both apoptotic (22, 68, 69) 
